Cargando…

The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation

SIMPLE SUMMARY: Decades of research efforts aiming to identify a new therapy for reducing mortality rates in metastatic uveal melanoma (UM) have not been successful. While ß-blockers are already used as the gold standard in other tumors, e.g., infantile haemangiomas, UM has not received much attenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Farhoumand, Lina S., Fiorentzis, Miltiadis, Kraemer, Miriam M., Sak, Ali, Stuschke, Martin, Rassaf, Tienush, Hendgen-Cotta, Ulrike, Bechrakis, Nikolaos E., Berchner-Pfannschmidt, Utta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264933/
https://www.ncbi.nlm.nih.gov/pubmed/35804869
http://dx.doi.org/10.3390/cancers14133097
_version_ 1784743079737032704
author Farhoumand, Lina S.
Fiorentzis, Miltiadis
Kraemer, Miriam M.
Sak, Ali
Stuschke, Martin
Rassaf, Tienush
Hendgen-Cotta, Ulrike
Bechrakis, Nikolaos E.
Berchner-Pfannschmidt, Utta
author_facet Farhoumand, Lina S.
Fiorentzis, Miltiadis
Kraemer, Miriam M.
Sak, Ali
Stuschke, Martin
Rassaf, Tienush
Hendgen-Cotta, Ulrike
Bechrakis, Nikolaos E.
Berchner-Pfannschmidt, Utta
author_sort Farhoumand, Lina S.
collection PubMed
description SIMPLE SUMMARY: Decades of research efforts aiming to identify a new therapy for reducing mortality rates in metastatic uveal melanoma (UM) have not been successful. While ß-blockers are already used as the gold standard in other tumors, e.g., infantile haemangiomas, UM has not received much attention. In the present study, we investigated ß-blockers to demonstrate their anti-tumor potential for the treatment of UM. Of the ß-blockers tested, carvedilol was able to block tumor cell viability and the long-term survival of the cells. Considering that brachytherapy is one of the most efficient local therapies for UM, the concurrent treatment of carvedilol and irradiation was performed, which resulted in additive effects. The anti-tumor properties of ß-blockers described in this study could lead to a new co-adjuvant treatment of UM with the aim to reduce the rate of metastasis and thus mortality. ABSTRACT: Uveal melanoma (UM) is the most common intraocular tumor in adults. Despite local tumor control, no effective therapy has been found to prevent metastasis, resulting in a high mortality rate. In the present study, we evaluated the anti-tumor potential of non-selective ß-blockers in 3D tumor spheroids grown from UM cell lines. Of the various ß-blockers tested, carvedilol and its enantiomers were most potent in decreasing the viability of Mel270 spheroids. Carvedilol at a concentration of 10–50 µM significantly elicited cytotoxicity and induced apoptosis in spheroid cells. In result, carvedilol inhibited tumor spheroid growth and compactness, and furthermore prevented the long-term survival and repopulation of spreading spheroid cells. The drug sensitivity of the different spheroids grown from Mel270, 92-1, UPMD2, or UPMM3 cell lines was dependent on 3D morphology rather than on high-risk cytogenetic profile or adrenergic receptor expression levels. In fact, the monosomy-3-containing UPMM3 cell line was most responsive to carvedilol treatment compared to the other cell lines. The concurrent treatment of UPMM3 spheroids with carvedilol and 5 or 10 Gy irradiation revealed additive cytotoxic effects that provided tumor control. Collectively, our data demonstrate the anti-tumor properties of carvedilol and its enantiomers, which may serve as candidates for the co-adjuvant therapy of UM.
format Online
Article
Text
id pubmed-9264933
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92649332022-07-09 The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation Farhoumand, Lina S. Fiorentzis, Miltiadis Kraemer, Miriam M. Sak, Ali Stuschke, Martin Rassaf, Tienush Hendgen-Cotta, Ulrike Bechrakis, Nikolaos E. Berchner-Pfannschmidt, Utta Cancers (Basel) Article SIMPLE SUMMARY: Decades of research efforts aiming to identify a new therapy for reducing mortality rates in metastatic uveal melanoma (UM) have not been successful. While ß-blockers are already used as the gold standard in other tumors, e.g., infantile haemangiomas, UM has not received much attention. In the present study, we investigated ß-blockers to demonstrate their anti-tumor potential for the treatment of UM. Of the ß-blockers tested, carvedilol was able to block tumor cell viability and the long-term survival of the cells. Considering that brachytherapy is one of the most efficient local therapies for UM, the concurrent treatment of carvedilol and irradiation was performed, which resulted in additive effects. The anti-tumor properties of ß-blockers described in this study could lead to a new co-adjuvant treatment of UM with the aim to reduce the rate of metastasis and thus mortality. ABSTRACT: Uveal melanoma (UM) is the most common intraocular tumor in adults. Despite local tumor control, no effective therapy has been found to prevent metastasis, resulting in a high mortality rate. In the present study, we evaluated the anti-tumor potential of non-selective ß-blockers in 3D tumor spheroids grown from UM cell lines. Of the various ß-blockers tested, carvedilol and its enantiomers were most potent in decreasing the viability of Mel270 spheroids. Carvedilol at a concentration of 10–50 µM significantly elicited cytotoxicity and induced apoptosis in spheroid cells. In result, carvedilol inhibited tumor spheroid growth and compactness, and furthermore prevented the long-term survival and repopulation of spreading spheroid cells. The drug sensitivity of the different spheroids grown from Mel270, 92-1, UPMD2, or UPMM3 cell lines was dependent on 3D morphology rather than on high-risk cytogenetic profile or adrenergic receptor expression levels. In fact, the monosomy-3-containing UPMM3 cell line was most responsive to carvedilol treatment compared to the other cell lines. The concurrent treatment of UPMM3 spheroids with carvedilol and 5 or 10 Gy irradiation revealed additive cytotoxic effects that provided tumor control. Collectively, our data demonstrate the anti-tumor properties of carvedilol and its enantiomers, which may serve as candidates for the co-adjuvant therapy of UM. MDPI 2022-06-23 /pmc/articles/PMC9264933/ /pubmed/35804869 http://dx.doi.org/10.3390/cancers14133097 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Farhoumand, Lina S.
Fiorentzis, Miltiadis
Kraemer, Miriam M.
Sak, Ali
Stuschke, Martin
Rassaf, Tienush
Hendgen-Cotta, Ulrike
Bechrakis, Nikolaos E.
Berchner-Pfannschmidt, Utta
The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation
title The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation
title_full The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation
title_fullStr The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation
title_full_unstemmed The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation
title_short The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation
title_sort adrenergic receptor antagonist carvedilol elicits anti-tumor responses in uveal melanoma 3d tumor spheroids and may serve as co-adjuvant therapy with radiation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264933/
https://www.ncbi.nlm.nih.gov/pubmed/35804869
http://dx.doi.org/10.3390/cancers14133097
work_keys_str_mv AT farhoumandlinas theadrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT fiorentzismiltiadis theadrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT kraemermiriamm theadrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT sakali theadrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT stuschkemartin theadrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT rassaftienush theadrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT hendgencottaulrike theadrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT bechrakisnikolaose theadrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT berchnerpfannschmidtutta theadrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT farhoumandlinas adrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT fiorentzismiltiadis adrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT kraemermiriamm adrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT sakali adrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT stuschkemartin adrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT rassaftienush adrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT hendgencottaulrike adrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT bechrakisnikolaose adrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation
AT berchnerpfannschmidtutta adrenergicreceptorantagonistcarvedilolelicitsantitumorresponsesinuvealmelanoma3dtumorspheroidsandmayserveascoadjuvanttherapywithradiation